|Day Low/High||47.07 / 47.82|
|52 Wk Low/High||44.30 / 63.69|
Jim Cramer says this market is influenced by tariffs and trade talks -- with the Federal Reserve and the economy playing second fiddle.
Jim Cramer takes a look at Applied Materials, HP, Lam Research, Schlumberger, PBF Energy, Targa Resources, Mallinckrodt and more.
Two-time Emmy Award winner Sterling K. Brown ( This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis.
Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, in New York.
Bristol-Myers Squibb Company (NYSE: BMY) today announced the Phase 3 CheckMate -498 trial evaluating Opdivo (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase...
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") today announced that it priced its previously announced private offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $19 billion (collectively, the...
This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.
As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.
Jim Cramer says that although a sell-off can breed a buying opportunity, investors need to worry about sky-high IPOs and other signs of froth.
Nothing’s wrong with a market correction – the Russell 2000 even outperformed – but keep your eyes on the declining McClellan Summation Index.
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today that the requisite number of consents have been received to adopt proposed amendments with respect to all outstanding notes of Celgene Corporation (NASDAQ:CELG) ("Celgene").
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") today announced that, subject to market and other conditions, it intends to commence a private offering (the "Offering") to sell senior unsecured notes (the "Notes").
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.
Bristol-Myers Squibb posted stronger than-expected first quarter earnings Thursday, and boosted one of its key profit forecast, after seeing off an activist challenge to its $74 billion takeover of cancer specialist Celgene earlier this month.
Global stocks pared gains Thursday, as weakening data and dovish central bank actions added to concerns over the pace of world growth and offset the bullish tenor from last night's after-the-bell earnings on Wall Street.
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robust operating performance across the portfolio.
U.S. stock futures trade mixed on Thursday; Amazon, Intel and Comcast report earnings; Microsoft jumps as third-quarter earnings beat analysts' expectations; Facebook sets aside $3 billion for expected fine from Federal Trade Commission.
Bristol-Myers Squibb revenue expected to rise 10.8% to $5.8 billion.
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb) announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation (NASDAQ:CELG) ("Celgene") , of an exchange offer for any and all outstanding...
Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.
Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company's pending merger with Celgene Corporation (NASDAQ:CELG) at the...
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were...
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.
Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene's (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co.
NEW YORK, March 29, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), a shareholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY), today provided the following statement on its investment...
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.